Use of botulinum toxins in cancer therapy.
A recent study has demonstrated for the first time that botulinum neurotoxin (BoNT) briefly opens tumour vessels, allowing more effective destruction of cancer cells by radiotherapy and chemotherapy. This review discusses the implications of BoNTs in cancer treatment. After briefly reviewing the different BoNT serotypes, their pharmacological activities and their general use in medicine, the authors focus on their possible application in cancer and describe how BoNTs have been used so far to treat spasm related to tumour or to therapies. By dissecting the mechanisms of action leading to a potentiation of anticancer therapy, it can be seen that BoNTs act by an effect on the tumour microenvironment rather than by a direct cytotoxic effect on tumour cells.
Ansiaux
Réginald
R
Biomedical Magnetic Resonance Unit, Department of Pharmaceutical Sciences, Avenue Mounier 73.40, B-1200 Brussels, Belgium.
Gallez
Bernard
B
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000138:chemical synthesis / Q000627:therapeutic use*; D004421:Dystonia / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D000970:Antineoplastic Agents; D001905:Botulinum Toxins